INTRODUCTION
• The first-generation, sst 2 -preferential somatostatin analogues octreotide LAR and lanreotide Autogel are the current standard of medical management in acromegaly. 1 • However, various studies have shown that many patients remain inadequately controlled despite receiving these somatostatin analogues. [2] [3] [4] [5] [6] [7] As such, there remains the need for a new treatment option in patients who are inadequately controlled on currently available therapies.
• Pasireotide is a multireceptor-targeted somatostatin analogue with higher affinity for sst 5 and slightly lower affinity for sst 2 , the two somatostatin receptors most prevalent on somatotroph adenomas, than octreotide and lanreotide. 8 • In a randomized, double-blind, Phase III study in patients with medically naïve acromegaly, pasireotide LAR showed significantly superior efficacy in providing biochemical control over octreotide LAR (31.3% vs 19.2%; P=0.007).
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• The current Phase III study (PAOLA) assessed the efficacy and safety of pasireotide LAR versus continued therapy with octreotide LAR and lanreotide Autogel in patients with inadequately controlled acromegaly.
METHODS

Patients
• Male and female patients aged ≥18 years with inadequately controlled acromegaly -Defined as mean growth hormone (GH) levels >2.5 μg/L and insulin-like growth factor 1 (IGF-1) >1.3 times the sex-and ageadjusted upper normal limit.
• All patients received octreotide LAR 30 mg or lanreotide Autogel 120 mg monotherapy for ≥6 months before screening.
Study Design and Endpoints
• Prospective, 24-week, multicentre, randomized, parallel-group study ( Figure 1 ).
• Patients randomized to: double-blind pasireotide LAR 40 mg/28 days or 60 mg/28 days; or continued treatment with open-label octreotide LAR or lanreotide Autogel (active control).
• Primary endpoint: proportion of patients achieving biochemical control (ie mean GH levels <2.5 μg/L and normalized IGF-1 levels) at 24 weeks.
• Key secondary endpoint: proportion of patients achieving normalized IGF-1 at 24 weeks.
• Other secondary endpoints included: proportion of patients achieving GH levels <2.5 μg/L; proportion of patients achieving tumour volume reduction >25%; change from baseline in symptoms of acromegaly and health-related quality of life (using AcroQoL
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). Safety and tolerability were also assessed. End of core phase 
Analysis
• All endpoints were comparisons between each dose of pasireotide LAR versus active control.
• The primary and key secondary endpoints were tested using an exact logistic regression model that adjusts for the randomization stratification factors.
• Efficacy analyses were conducted on the full analysis set, which comprised all randomized patients. The safety analysis set comprised all patients who received at least one dose of study drug with a valid post-baseline safety assessment.
RESULTS
Patient Population
• Overall, 198 patients were randomized to pasireotide LAR 40 mg (n=65), pasireotide LAR 60 mg (n=65) and active control (n=68) -Six randomized patients (n=2, 2 and 2, respectively) did not receive treatment because of administrative issues (n=3), consent withdrawal (n=2) and protocol deviation (n=1) -One additional patient (pasireotide LAR 60 mg) was treated but did not have any post-baseline assessments -59 (90.8%), 57 (87.7%) and 65 (95.6%) patients completed the 24-week study, respectively.
• Patient demographics, characteristics and disease history at baseline were generally similar across treatment groups ( Table 1) . (Figure 4) .
GH Levels
• Mean GH levels <2.5 μg/L at week 24 were observed in 35.4% and 43.1% of pasireotide LAR 40 mg and 60 mg patients, respectively, compared with 13.2% of patients in the active control group (Figures 2 and 3B ).
• Mean GH levels decreased from baseline to week 12 and remained stable to week 24 in both pasireotide LAR treatment groups; mean levels slightly decreased in the active control group (Figure 4 ). Table 2 -Most were of mild-to-moderate severity (grades 1/2) -A higher frequency of hyperglycaemia-related AEs was observed with pasireotide LAR compared with active control.
Other Efficacy Endpoints
• Serious AEs were reported in six patients (9.5%) in the pasireotide LAR 40 mg group, two (3.2%) in the pasireotide LAR 60 mg group and three (4.5%) in the active control group.
• Six patients discontinued because of an AE: diabetes mellitus (n=1 with pasireotide LAR 60 mg); hyperglycaemia (n=1 with pasireotide LAR 40 mg and n=3 with pasireotide LAR 60 mg); colon cancer (n=1 with pasireotide LAR 40 mg) -All were suspected to be related to study treatment, except the case of colon cancer.
• One AE (liver injury in the pasireotide LAR 40 mg group) required dose interruption/reduction. • There were no deaths. Note: AEs are presented in order of overall frequency and reported using the preferred terms recorded by the investigators; as such, a single patient may appear in more than one row for hyperglycaemia-related terms
CONCLUSIONS
• The Phase III PAOLA study met its primary and key secondary endpoint, demonstrating that pasireotide LAR 40 mg and 60 mg provide superior efficacy over continued treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg in patients with inadequately controlled acromegaly.
• Pasireotide LAR was well tolerated; the safety profile was generally similar to that observed in the active control group, except for a higher frequency and degree of hyperglycaemia.
• Pasireotide LAR could become the new standard pituitarydirected therapeutic option in patients with acromegaly inadequately controlled by first-generation somatostatin analogues.
